Research programme: anti-infectives - Emergent BioSolutions

Drug Profile

Research programme: anti-infectives - Emergent BioSolutions

Alternative Names: 2-pyridone based topoisomerase inhibitors (EV-035); EBX 205; EV 035 series - Emergent BioSolutions; EV-021; EV-035; EV-035a; EV-035b; EV-035c; EV-075; EV-086; GC-0146; GC-061; GC-063; GC-072

Latest Information Update: 19 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Evolva Biotech
  • Developer Emergent BioSolutions; United States Army Research Laboratory
  • Class Antibacterials; Pyridones; Small molecules
  • Mechanism of Action Immunomodulators; Type II bacterial DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anthrax; Burkholderia infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Discontinued Ebola virus infections; Escherichia coli infections; Influenza virus infections; Mycoses

Most Recent Events

  • 14 Jul 2018 Antimicrobial data from in vitro studies in Public health threats presented at ASM Microbe (ASMM - 2018)
  • 04 Jun 2018 Preclinical development in Bacterial infections, Methicillin-resistant Staphylococcus aureus infections, Anthrax and Burkholderia infections is ongoing in USA (PO) (Emergent Biosciences pipeline, June 2018)
  • 04 Jun 2018 Discontinued - Preclinical for Escherichia coli infections in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top